Author Topic: GUD.V - Knight Therapeutics  (Read 39579 times)

wisowis

  • Full Member
  • ***
  • Posts: 134
Re: GUD.V - Knight Therapeutics
« Reply #80 on: September 08, 2019, 10:44:58 AM »
Looks like they bought back ~4.6 million shares in July, or ~3% of the company.

I have a stupid question. Their NCIB says "[the company] may purchase up to a daily maximum of 88,853 Shares". Their Q2 update said "The NCIB commenced on July 11, 2019...As at August 6, 2019, the Company has purchased 4,657,235 common shares." Obviously this is well above 88k shares per trading day. I have also noticed they have been buying some large blocks, over 1 million shares in a day.

This seems to be contrary to the NCIB - are they allowed to do this? What are the rules governing it?

Thanks.


no_free_lunch

  • Hero Member
  • *****
  • Posts: 1638
Re: GUD.V - Knight Therapeutics
« Reply #81 on: October 08, 2019, 08:47:36 PM »
Just finally catching up on this one.

Thanks for your posts snowball, NERLYNX was a good find.  I don't know the exact number but it has significant potential.

I did 5 minutes of google work and found this on it.  The article references NERLYNX as neratinib but it's the same product.  It's not smoke, the product really works.

Quote
Results at 2 years of follow-up showed that treatment with neratinib led to a 51% reduction in the risk invasive disease recurrence or death at 2 years compared with placebo.

https://www.targetedonc.com/news/health-canada-approves-extended-adjuvant-neratinib-for-earlystage-hr-breast-cancer

snowball82

  • Sr. Member
  • ****
  • Posts: 378
Re: GUD.V - Knight Therapeutics
« Reply #82 on: October 09, 2019, 02:29:04 AM »
Just finally catching up on this one.

Thanks for your posts snowball, NERLYNX was a good find.  I don't know the exact number but it has significant potential.

I did 5 minutes of google work and found this on it.  The article references NERLYNX as neratinib but it's the same product.  It's not smoke, the product really works.

Quote
Results at 2 years of follow-up showed that treatment with neratinib led to a 51% reduction in the risk invasive disease recurrence or death at 2 years compared with placebo.

https://www.targetedonc.com/news/health-canada-approves-extended-adjuvant-neratinib-for-earlystage-hr-breast-cancer

Welcome, GUD seems also interested by shopping in Latin America

https://www.grupobiotoscana.com/en/

 https://braziljournal.com/eurofarma-e-knight-therapeutics-disputam-a-biotoscana

snowball82

  • Sr. Member
  • ****
  • Posts: 378
Re: GUD.V - Knight Therapeutics
« Reply #83 on: October 21, 2019, 06:57:13 AM »
Transformational acquisition establishes Knight as a premiere pan-American (ex-US) specialty pharma company

Executes on Knight’s strategy to build a Rest of World specialty pharmaceutical company and become the partner of choice for top pharmaceutical companies for pan-American (ex-US) in-licensing opportunities
Strong regional infrastructure and management team with a unique footprint across 10 countries in Latin America
Established and diversified portfolio of innovative products across specialty therapeutic areas
Significant organic growth opportunity via robust in-licensing pipeline and a solid platform for future growth via acquisition
Grupo Biotoscana generated revenue of BRL 754 million or C$240 million and adjusted EBITDA of BRL 154 million or C$49 million for the last twelve month period ending June 30, 2019

https://www.globenewswire.com/news-release/2019/10/21/1932427/0/en/Knight-Therapeutics-to-Acquire-Grupo-Biotoscana-Establishing-a-Latin-American-Growth-Platform.html

no_free_lunch

  • Hero Member
  • *****
  • Posts: 1638
Re: GUD.V - Knight Therapeutics
« Reply #84 on: October 21, 2019, 11:23:55 AM »
$189m acquisition.  They have over half of their cash deployed now.

FiveSigma

  • Jr. Member
  • **
  • Posts: 69
Re: GUD.V - Knight Therapeutics
« Reply #85 on: October 21, 2019, 12:10:17 PM »
It's CAD $369M for the whole business.


no_free_lunch

  • Hero Member
  • *****
  • Posts: 1638
Re: GUD.V - Knight Therapeutics
« Reply #87 on: October 22, 2019, 11:39:22 AM »
I went through the slides from knight.  I am glad that they are deploying capital (as 5sigma points out, they are now something like 75% deployed) but it's not immediately clear the benefit.  They mention access to capital and access to knight's existing contacts.  I am just not familiar enough with the industry to determine how much synergy that brings to the table.

At least this will silence some of the complaints that knight raised capital and is just sitting on the money and collecting a pay-check.

snowball82

  • Sr. Member
  • ****
  • Posts: 378
Re: GUD.V - Knight Therapeutics
« Reply #88 on: October 24, 2019, 03:57:42 AM »
Knight Therapeutics and SIFI S.p.A. Announce Approval of NETILDEX™ in Canada

http://gudknight.irpass.com/ViewEmail.asp?b=2320&id=184466&p=2170075&I=1237180-i8G3t5c9s4